

## RD General Agenda Topics – June 3, 2021

### Briefings for Michal

- PRIA/registration overview 2/23<sup>rd</sup> (complete)
- Dicamba 2/18<sup>th</sup> (complete)
- Sulfoxaflor 3/4<sup>th</sup> (complete)
- Pet incidents 3/31<sup>st</sup> (complete)
- FDA/EPA jurisdiction 4/12<sup>th</sup> (complete)
- SW2 revocation options 5/3<sup>rd</sup> (complete)
- Antibiotics 5/17<sup>th</sup> (complete)

### New Active Ingredients (include original PRIA date)

- Tetraniliprole – completed!
- Broflanilide – completed!
- Picarbutrazox – completed!
- Fluxametamide – completed!
- Fluindapyr – completed!
- Trifludimoxazin – completed!
- Rekleml – PD being developed. PRIA date **7/19/21** (Original PRIA date 4/19/21) (IVB3). Partial ESA – causing delays
- Ipflufenquin – PD being developed. PRIA date **7/30/31** (Original PRIA date 4/19/21) (FB). Working on ESA – causing delays
- L-Glufosinate Ammonium – Risk Assessment phase. PRIA date 10/12/2021 (FHB). ESA issue. Briefing Ed on ESA and resource considerations in June

### Other Chemical Actions

- Dicamba
  - Bayer and BASF requesting feedback on pending pre-mixes

## Ex. 5 Deliberative Process (DP)

- **USDA conducting EIS** (instead of EA) on dicamba resistant corn; issued a 60-day public comment period 5/8th; citing EPA's cancellation order and 2020 decision. Discussed with OPMP. Comment period extended to 6/28. Coordinating with AO's OP and regions; OPP team recommends not sending substantive comments at this point
- **24 (c)s** –
  - NC – denial 3/15<sup>th</sup>
  - TN – denial 4/9<sup>th</sup>
  - GA – denial 4/23<sup>rd</sup>
  - **TX – Notice of intent to deny NLT 6/18<sup>th</sup>; denial NLT 6/30<sup>th</sup> – draft NOID ready for OPP-IO**
- **Antibiotics** – will need to brief the new team (FB)

- Briefed Michal 5/17<sup>th</sup>; Received policy feedback on the antibiotic issue; Oxytet – cherry PRIA date of June – delay the action while we work on policy approach.
- **Inorganic Bromide** – R10 meeting with OPP; APHIS meeting with Michal – requesting increase in tolerance on alfalfa (Dan R)
- **Cyclaniliprole/flonicamid** – first residential use; public process; published proposal!
- **Seresto** – pet collar with high rate of incidents (death and neuro); press inquiries; 6a2 letter sent; updated desk statement to include factual information on FDA vs. EPA; received information from Elanco; team is developing a schedule
- **Aldicarb** – AgLogic is not interested in voluntary cancellation
- **Enlist** – Extension of the registration (expires end of 2021); Corteva is looking for a decision to inform seed purchase for soybeans; OGC advises an to update ESA finding

### Other Actions - AA-Level/OD/High Visibility Items

- FDA/EPA jurisdiction – Michal follow up complete; team identified appropriate “model” MOUs and sent talking points; next steps on reaching out?
- COVID-19 Activities – Sect 18s –
  - SW2 –
    - revocation of existing AR, TX S18s based on science and violations (week of June 23rd)
      - Discussing whether AR or OK want to request revocation; OK is requesting revocation – **grant the request next week (Ed’s signature)**
  - Grignard – reviews complete; working on authorization letters – meeting with

## Ex. 5 Deliberative Process (DP)

amendment to TN and GA)

- Kraton – completed!
- Ionopure Air – risk issues
- Acteev Facemasks
- OIG Audits

## Ex. 5 Deliberative Process (DP)

- **PFAS** – RD working with Clark on submissions
  - Definition issue – working to bring Jeff D. up to speed
  - 6a2 notification? Nothing planned yet
- **Inerts** supply issue – phase 1 completed!; phase 2 – working on the draft response without AD
- **Inert – Fragrance petition (Pat Quinn)** – 2 petition responses scheduled for OGC review in June (Kerry); other petition responses will follow within existing resource constraints

- **CRP** (Child resistant Packaging) testing – industry has requested flexibilities in testing requirements due to COVID impacts; CPSC (whose regulations we use) have issued similar flexibilities. Team recommends issuing some but not all flexibilities. Next steps- COVID workgroup

### **International**

- Bi-monthly meeting with PMRA 5/11<sup>th</sup> – antibiotics, Seresto – complete; next meeting July

### **Business/process/technology**

- ISB – FEP/21-day backlog:
  - backlog addressed by end of April; RD SWAT team addressing newer receipts
  - Working to complete RD SWAT actions
- eCSF/OPPEL – eCSF May 9<sup>th</sup> soft launch; OPPEL -TBD
- MRL – structured data for OPP and share with FDA; FDA is applying for internal grant – supports OPP digital transformation; OPP serving as reviewer

### **Speaking Engagements –**

- HCPA mid-year meeting – Marietta 5/27<sup>th</sup>
- MRL workshop – Nancy Fitz 5/27<sup>th</sup>

## **Ex. 5 Deliberative Process (DP)**

### **CA topics (Karen Morrison):**

- Missing environmental hazard statements – RD BC's are generating a response